Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0T4XV
|
|||
Former ID |
DIB004937
|
|||
Drug Name |
SL-18.1616
|
|||
Indication | Insomnia [ICD-11: 7A00-7A0Z] | Terminated | [1] | |
Company |
Sanofi-Synthelabo
|
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Melatonin receptor type 1A (MTNR1A) | Target Info | Agonist | [2] |
KEGG Pathway | Neuroactive ligand-receptor interaction | |||
Circadian entrainment | ||||
Reactome | Class A/1 (Rhodopsin-like receptors) | |||
G alpha (i) signalling events | ||||
WikiPathways | GPCRs, Class A Rhodopsin-like | |||
Small Ligand GPCRs | ||||
GPCR ligand binding | ||||
GPCR downstream signaling |
References | Top | |||
---|---|---|---|---|
REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800014349) | |||
REF 2 | US patent application no. 2005,016,4987, Melatonin combination therapy for improving sleep quality. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.